RE:RE:RE:RE:prophetoffact on ignore...Ya, I just don't like folks who alternate between pumping and bashing stocks. Here's one of your posts from 2017 when you were in bashing mode. Mostly not event-specific complaints but general FUD posed as "questions" that could be posted at any time. How do explain that? How do explain your multi-year alternating between pumping and bashing? Are you doing that on every board you visit?
digitel
November 29, 2017 - 12:37 PM
RE:Down 4¢ on 2,250 shares.
"Now there's a great big opinion being expressed in the market!"
It's the whole world, including the insiders, not stepping up to buy the shares even one cent higher and letting it fall. That's the opinion that should concern us; especially at this price level. Where's the liquidity?
And if BTI is having a hard time generating liquidity at these prices, including from insiders, what price may they need to finance/dilute given the dwindling cash position? And why is the stock closer to its 52-week low than the high of last year given the new management. The goal should have been to get the warrant money on the strength of the new management team and the validation and the plan. Why isn't the market showing buy-in but instead 'negative validation' over seven months into the new leadership and plans unfolding?
And what happened with Shire, Medimmune, Astellas, Scarpa, the foot dragging concerning the Herceptin product given an IND filing was to be filed in 2015, and "$18 and 4, maybe more", fireworks, and hockey stick like revenue, Shadow Lake Group, etc.? What about those 'bids' - the bids of industry? Why didn't Gubiz ever buy shares?
How easily will BTI be able to finance given current liquidity and the insiders lack of skin in the game given their stock purchases? drjekl mentions how the financings have been successively lower over the years. If industry has voiced its opinion, and management has only purchased the stock it has after all of the talks with industry and with its insider knowledge, where does that leave the market? Have we seen all they have?
This company appears to have lost more licensing deals vs. those still active(Medimmune, Astellas, vs. Vaccinex); but what is up with Vaccinex over one year after it signed its deal that it never even bothered to press release on its website?
Why has this been so difficult vs. expectations?